Profound Medical Annual and Special Meeting of Shareholders Voting Results
May 20 2020 - 4:30PM
Profound Medical Corp. (TSX: PRN; NASDAQ: PROF)
(“
Profound” or the “
Company”) is
pleased to announce the voting results from its Annual and Special
Meeting of Shareholders that was held today (the
“
Meeting”). A total of 8,067,967 common shares,
representing 50.176% of the common shares outstanding, were
represented in person and by proxy at the Meeting.
All of the matters put forward before the
shareholders, as set out in the Company’s management information
circular dated April 13, 2020 (the “Information
Circular”), were approved by the requisite majority of
votes cast at the Meeting.
Election of Directors
At the meeting, the shareholders of the Company
elected all seven nominees for the board of directors (the
“Board”). Detailed results of the voting in
respect of the election of directors are as follows:
Nominee |
For |
% For |
Withheld |
% Withheld |
Arun Menawat |
8,067,688 |
99.997% |
279 |
0.003% |
Brian Ellacott |
8,066,328 |
99.980% |
1,639 |
0.02% |
Steve Forte |
8,067,888 |
99.999% |
79 |
0.001% |
Kenneth Galbraith |
7,923,095 |
98.204% |
144,872 |
1.796% |
Linda Maxwell |
8,067,336 |
99.992% |
631 |
0.008% |
Jean-François Pariseau |
8,065,976 |
99.975% |
1,991 |
0.025% |
Arthur Rosenthal |
8,065,776 |
99.973% |
2,191 |
0.027% |
Other Matters
The Company’s shareholders also approved the
appointment of PricewaterhouseCoopers LLP as the auditor for the
Company to hold office until the close of the next annual meeting
or until its successor is duly appointed, at such remuneration as
may be determined by the Board and an ordinary resolution
confirming, approving and adopting the Company’s long-term
incentive plan, as more particularly described in the Information
Circular. Detailed voting results for all resolutions will be
posted under the Company’s profile at www.sedar.com.
About Profound Medical Corp.
Profound is a commercial-stage medical device
company that develops and markets customizable, incision-free
therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a
technology that combines real-time MRI, robotically-driven
transurethral ultrasound and closed-loop temperature feedback
control. TULSA-PRO® is designed to provide customizable and
predictable radiation-free ablation of a surgeon-defined prostate
volume while actively protecting the urethra and rectum to help
preserve the patient’s natural functional abilities. TULSA-PRO® has
the potential to be a flexible technology in customizable prostate
ablation, including intermediate stage cancer, localized
radio-recurrent cancer, retention and hematuria palliation in
locally advanced prostate cancer, and the transition zone in large
volume benign prostatic hyperplasia (BPH). TULSA-PRO® is CE marked,
Health Canada approved and 510(k) cleared by the U.S. Food and Drug
Administration.
Profound is also commercializing SONALLEVE®, an
innovative therapeutic platform that is CE marked for the treatment
of uterine fibroids and palliative pain treatment of bone
metastases. SONALLEVE® has also been approved by the China Food and
Drug Administration for the non-invasive treatment of uterine
fibroids. The Company is in the early stages of exploring
additional potential treatment markets for SONALLEVE® where the
technology has been shown to have clinical application, such as
non-invasive ablation of abdominal cancers and hyperthermia for
cancer therapy.
For further information, please contact:
Stephen KilmerInvestor
Relationsskilmer@profoundmedical.com T: 647-872-4849
Profound Medical (NASDAQ:PROF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Profound Medical (NASDAQ:PROF)
Historical Stock Chart
From Apr 2023 to Apr 2024